Comparison of effectiveness and safety of nirmatrelvir/ritonavir versus sotrovimab for COVID-19: a systematic review and meta-analysis

References

• Matrajt L, Brown ER, Cohen MS, et al. Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study. BMC Infect Dis. 2022;22(1):1–16. doi: 10.1186/s12879-022-07639-1
   PubMed Web of Science ®Google Scholar
• Chen X, Luo D, Mei B, et al. Immunogenicity of COVID-19 vaccines in solid organ transplant recipients: a systematic review and meta-analysis. Clin Microbiol Infect. 2023;29(4):441–456. doi: 10.1016/j.cmi.2022.12.004
   PubMed Web of Science ®Google Scholar
• Alfishawy M, Elbendary A, Mohamed M, et al. COVID-19 mortality in transplant recipients. Int J Organ Transplant Med. 2020;11(4):145–162.
   PubMed Web of Science ®Google Scholar
• Yin J, Chen Y, Li Y, et al. Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis. Inter J Infect Dis. 2022 Nov;124:212–223. doi: 10.1016/j.ijid.2022.10.005
   PubMed Web of Science ®Google Scholar
• Dzinamarira T, Murewanhema G, Chitungo I, et al. Risk of mortality in HIV-infected COVID-19 patients: a systematic review and meta-analysis. J Infect Public Health. 2022;15(6):654–661. doi: 10.1016/j.jiph.2022.05.006
   PubMed Web of Science ®Google Scholar
• van den Berg JM, Remmelzwaal S, Blom MT, et al. Effectiveness of COVID-19 vaccines in adults with diabetes mellitus: a systematic review. Vaccines. 2022;11(1):24. doi: 10.3390/vaccines11010024
   Web of Science ®Google Scholar
• Bepouka B, Odio O, Mangala D, et al. Diabetes mellitus is associated with higher COVID-19 mortality rates in Sub-Saharan Africa: a systematic review and meta-analysis. Cureus. 2022;14(7):e26877. doi: 10.7759/cureus.26877
   PubMed Web of Science ®Google Scholar
• Rabie AM. Future of the current anticoronaviral agents: a viewpoint on the validation for the next COVIDs and pandemics. Biocell. 2023;47(10):2133–2139. doi: 10.32604/biocell.2023.030057
   Web of Science ®Google Scholar
• Eltayb WA, Abdalla M, Rabie AM. Novel investigational anti-SARS-CoV-2 agent ensitrelvir “S-217622”: a very promising potential universal broad-spectrum antiviral at the therapeutic frontline of coronavirus species. ACS Omega. 2023;8(6):5234–5246. doi: 10.1021/acsomega.2c03881
   PubMedGoogle Scholar
• Rabie AM, Abdalla M. Forodesine and riboprine exhibit strong anti-SARS-CoV-2 repurposing potential: In silico and in vitro studies. ACS Bio & Med Chem Au. 2022;2(6):565–585. doi: 10.1021/acsbiomedchemau.2c00039
   PubMedGoogle Scholar
• Panahi Y, Gorabi AM, Talaei S, et al. An overview on the treatments and prevention against COVID-19. Virol J. 2023;20(1):1–29. doi: 10.1186/s12985-023-01973-9
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu M, Li Z, et al. Molnupiravir for treatment of adults with mild or moderate COVID-19: a systematic review and meta-analysis of randomised controlled trials. Clin Microbiol Infect. 2023;29(8):979–999. doi: 10.1016/j.cmi.2023.04.014
   PubMed Web of Science ®Google Scholar
• Amstutz A, Speich B, Mentré F, et al. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. Lancet Respir Med. 2023;11(5):453–464. doi: 10.1016/S2213-2600(22)00528-8
   PubMed Web of Science ®Google Scholar
• Tian F, Chen Z, Feng Q. Nirmatrelvir–ritonavir compared with other antiviral drugs for the treatment of COVID‐19 patients: a systematic review and meta‐analysis. J Med Virol. 2023;95(4):e28732. doi: 10.1002/jmv.28732
   PubMed Web of Science ®Google Scholar
• Amani B, Amani B. Efficacy and safety of nirmatrelvir/ritonavir (paxlovid) for COVID‐19: a rapid review and meta‐analysis. J Med Virol. 2023;95(2):e28441. doi: 10.1002/jmv.28441
   PubMed Web of Science ®Google Scholar
• Amani B, Amani B. Efficacy and safety of sotrovimab in patients with COVID‐19: a rapid review and meta‐analysis. Rev Med Virol. 2022;32(6):e2402. doi: 10.1002/rmv.2402
   PubMed Web of Science ®Google Scholar
• https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults
   Google Scholar
• Hashemian SMR, Sheida A, Taghizadieh M, et al. Paxlovid (Nirmatrelvir/Ritonavir): a new approach to covid-19 therapy? Biomed Pharmacother. 2023;162:114367. doi: 10.1016/j.biopha.2023.114367
   PubMed Web of Science ®Google Scholar
• Li H, Xiang H, He B, et al. Nirmatrelvir plus ritonavir remains effective in vaccinated patients at risk of progression with COVID-19: A systematic review and meta-analysis. J Glob Health. 2023;13. doi: 10.7189/jogh.13.06032
   Web of Science ®Google Scholar
• Heo Y-A. Sotrovimab: first approval. Drugs. 2022;82(4):477–484. doi: 10.1007/s40265-022-01690-7
   PubMed Web of Science ®Google Scholar
• https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization
   Google Scholar
• Drysdale M, Gibbons DC, Singh M, et al. Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during omicron BA. 2 subvariant predominance: a systematic literature review. medRxiv. 2023, Mar 09. 23287034.
   Google Scholar
• Miyashita N, Nakamori Y, Ogata M, et al. Clinical efficacy of the neutralizing antibody therapy sotrovimab in patients with SARS-CoV-2 omicron BA. 1 and BA. 2 subvariant infections. Viruses. 2023;15(6):1300. doi: 10.3390/v15061300
   PubMed Web of Science ®Google Scholar
• Cegolon L, Pol R, Simonetti O, et al. Molnupiravir, Nirmatrelvir/Ritonavir, or sotrovimab for high-risk COVID-19 patients infected by the omicron variant: hospitalization, mortality, and Time until negative swab test in real life. Pharmaceuticals. 2023;16(5):721. doi: 10.3390/ph16050721
   Web of Science ®Google Scholar
• Manciulli T, Spinicci M, Rossetti B, et al. Safety and efficacy of outpatient treatments for COVID-19: real-life data from a regionwide cohort of high-risk patients in Tuscany, Italy (the FEDERATE cohort). Viruses. 2023;15(2):438. doi: 10.3390/v15020438
   PubMed Web of Science ®Google Scholar
• Radcliffe C, Palacios CF, Azar MM, et al. Real-world experience with available, outpatient COVID-19 therapies in solid organ transplant recipients during the omicron surge. Am J Transplant. 2022;22(10):2458–2463. doi: 10.1111/ajt.17098
   PubMed Web of Science ®Google Scholar
• Kauer V, Totschnig D, Augustin M, et al. Efficacy and tolerability of Sotrovimab, Molnupiravir and Nirmatrelvir/Ritonavir for non-hospitalized patients at high risk for COVID-19: a retrospective, single-center analysis. J Clin Toxicol. 2023;13:544.
   Google Scholar
• Mazzotta V, Cozzi Lepri A, Colavita F, et al. Viral load decrease in SARS‐CoV‐2 BA. 1 and BA. 2 omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents. J Med Virol. 2023;95(1):e28186. doi: 10.1002/jmv.28186
   PubMed Web of Science ®Google Scholar
• Gleeson S, Martin P, Thomson T, et al. Kidney transplant recipients and omicron: outcomes, effect of vaccines and the efficacy and safety of novel treatments. medRxiv. 2022. doi: 10.1101/2022.05.03.22274524
   Google Scholar
• Drysdale M, Tibble H, Patel V, et al. Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals or no treatment in Scotland. medRxiv. 2023, Jun 09. 23291195.
   Google Scholar
• Evans A, Qi C, Adebayo JO, et al. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: a retrospective cohort study. J Infect. 2023;86(4):352–360. doi: 10.1016/j.jinf.2023.02.012
   PubMed Web of Science ®Google Scholar
• Patel V, Yarwood MJ, Levick B, et al. Characteristics and outcomes of patients with COVID-19 at high-risk of disease progression receiving sotrovimab, oral antivirals or no treatment in England. medRxiv. 2022. doi: 10.1101/2022.11.28.22282808
   Google Scholar
• Vora S, Englund J, Trehan I, et al. Monoclonal antibody and antiviral therapy for treatment of mild-to-moderate COVID-19 in pediatric patients (preprint). 2022.
   Google Scholar
• Zheng B, Tazare J, Nab L, et al. Comparative effectiveness of paxlovid versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised patients: observational cohort study using the OpenSAFELY platform. medRxiv. 2023, Jan. 20. 23284849.
   Google Scholar
• Lasagna A, Cassaniti I, Lilleri D, et al. Effectiveness of the available early therapies in reducing severe COVID-19 in non-hospitalized patients with solid tumors on active treatment. Front Med (Lausanne). 2022;9:1036473. doi: 10.3389/fmed.2022.1036473
   PubMed Web of Science ®Google Scholar
• Marx K, Kalbitz S, Kellner N, et al. COVID-19 treatment strategies with drugs centrally procured by the German Federal Ministry of Health in a representative tertiary care hospital: a temporal analysis. GMS Infect Dis. 2023;11:11. doi: 10.3205/id000083
   Google Scholar
• Tamzali Y, Lundy A, Bleibtreu A, et al. Covid-19 early curative treatments in kidney transplant recipients: is it really reasonable at the omicron era? Nephrol Ther. 2023;1(1):1–6. doi: 10.1684/ndt.2023.44
   Google Scholar
• Pinargote-Celorio H, Otero-Rodríguez S, González-de-la-Aleja P, et al. Mild SARS-CoV-2 infection in vulnerable patients: implementation of a clinical pathway for early treatment. Enfermedades infecciosas y microbiologia clinica (English ed). 2023; doi: 10.1016/j.eimce.2023.03.003
   Google Scholar
• Lahouati M, Cazanave C, Labadie A, et al. Outcomes of targeted treatment in immunocompromised patients with asymptomatic or mild COVID-19: a retrospective study. Sci Rep. 2023;13(1):15357. doi: 10.1038/s41598-023-42727-5
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1–9. doi: 10.1186/2046-4053-4-1
   PubMed Web of Science ®Google Scholar
• Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355.
   Google Scholar
• Martin-Blondel G, Marcelin A-G, Soulié C, et al. Time to negative PCR conversion amongst high-risk patients with mild-to-moderate omicron BA. 1 and BA. 2 COVID-19 treated with sotrovimab or nirmatrelvir. Clin Microbiol Infect. 2023;29(4): 543.e5–543.e9. doi: 10.1016/j.cmi.2022.12.016
   PubMed Web of Science ®Google Scholar
• Minotti C, Mengato D, De Pieri M, et al. Early treatments of fragile children with COVID-19—results of CLEVER (children COVID early treatment), a retrospective, observational study. Viruses. 2023;15(1):192. doi: 10.3390/v15010192
   PubMed Web of Science ®Google Scholar
• Tian H, Yang C, Song T, et al. Efficacy and safety of paxlovid (nirmatrelvir/ritonavir) in the treatment of COVID‐19: an updated meta‐analysis and trial sequential analysis. Rev Med Virol. 2023;33(5):e2473. doi: 10.1002/rmv.2473
   PubMed Web of Science ®Google Scholar
• Gliga S, Lübke N, Killer A, et al. Rapid selection of sotrovimab escape variants in severe acute respiratory syndrome coronavirus 2 omicron-infected immunocompromised patients. Clinical Infectious Diseases. 2023;76(3):408–415. doi: 10.1093/cid/ciac802
   PubMedGoogle Scholar
• Huygens S, Oude Munnink B, Gharbharan A, et al. Sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the severe acute respiratory syndrome coronavirus 2 omicron variant. Clinical Infectious Diseases. 2023;76(3):e507–e509. doi: 10.1093/cid/ciac601
   PubMedGoogle Scholar
• Birnie E, Biemond JJ, Appelman B, et al. Development of resistance-associated mutations after sotrovimab administration in high-risk individuals infected with the SARS-CoV-2 omicron variant. JAMA. 2022;328(11):1104–1107. doi: 10.1001/jama.2022.13854
   PubMed Web of Science ®Google Scholar
• De Vito A, Colpani A, Poliseno M, et al. What is the efficacy of sotrovimab in reducing disease progression and death in people with COVID-19 during the omicron era? Answers from a real-life study. Viruses. 2023;15(8):1757. doi: 10.3390/v15081757
   PubMed Web of Science ®Google Scholar
• Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clinical Infectious Diseases. 2023;76(3):e342–e349. doi: 10.1093/cid/ciac443
   PubMed Web of Science ®Google Scholar
• Conti V, Sellitto C, Torsiello M, et al. Identification of drug interaction adverse events in patients with COVID-19: a systematic review. JAMA Netw Open. 2022;5(4):e227970. doi: 10.1001/jamanetworkopen.2022.7970
   PubMed Web of Science ®Google Scholar
• Marzolini C, Kuritzkes DR, Marra F, et al. Recommendations for the management of drug–drug interactions between the COVID‐19 antiviral nirmatrelvir/ritonavir (paxlovid) and comedications. Clin Pharmacol Ther. 2022;112(6):1191–1200. doi: 10.1002/cpt.2646
   PubMed Web of Science ®Google Scholar
• Davoutis E, Panou C, Stachika N, et al. Drug-drug interactions between COVID-19 drug therapies and antidepressants. Expert Opin Drug Metab Toxicol. 2023;19(12):937–950. ( just-accepted). doi: 10.1080/17425255.2023.2280750
   PubMed Web of Science ®Google Scholar